DALLAS, Feb. 10, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Cell Therapeutics Inc. (Nasdaq:CTIC). The report includes financial, comparative and investment analyses and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/CTIC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Cell Therapeutics Inc. (CTIC) is a biopharmaceutical company engaged in the development and commercialization of oncology drug therapies for the treatment of cancer. Its portfolio of trial therapies include phase III candidate drug therapy, Pixantrone, for the treatment of non-Hodgkin's lymphoma; phase II drug, Brostallicin, for the treatment of sarcoma; and OPAXIO for the treatment of non-small cell lung, ovarian, and other forms of cancer. The Company partnered with Novartis International Pharmaceuticals Ltd. and PG-TXL Co. L.P. for various drug development.
Message Board Search for CTIC: http://www.boardcentral.com/boards/CTIC
In the report, the analyst notes:
"If approved by the U.S. Food and Drug Administration (FDA), the market for CTIC's phase III drug candidate, Pixantrone, could reach more than $1 billion at market saturation. Data show that nine of 10 drugs completing phase III clinical trials eventually become commercial products.
"The Company's shares collapsed on February 8 following revelations of an increased possibility of a negative Food and Drug Administration (FDA) decision regarding the Company's lead drug candidate Pixantrone. Investors fear that a negative FDA decision may threaten the Company's ability to remain operational.
"Pixantrone is presently under review by the Oncologic Drugs Advisory Committee (ODAC), a committee that advises the FDA. Documents released by the FDA indicate problems with Pixantrone, giving investors hints of the ODAC review results."
To read the entire report visit: http://www.beaconequity.com/i/CTIC
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.